Drug Profile
PXS 5446
Alternative Names: PXS5446Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Pharmaxis
- Developer Syntara Limited
- Class Antifibrotics
- Mechanism of Action Protein-lysine 6-oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myelofibrosis
Most Recent Events
- 04 Dec 2023 Pharmaxis is now called Syntara Limited
- 28 Jan 2022 No recent reports of development identified for preclinical development in Myelofibrosis in Australia (Intraperitoneal)
- 09 Dec 2017 Pharmacodynamics data from preclinical studies in Myelofibrosis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)